Pseudomyxoma Peritonei Treatment

What is Pseudomyxoma Peritonei?

Pseudomyxoma Peritonei (PMP) is a rare pathology associating the presence of mucinous material in the abdominal cavity that is the peritoneal space where important organs and tissues are situated. It commonly occurs due to torsion of a mucinous cystic tumor; commonly appendiceal but can be of ovarian or colonic origin.

Advanced Pseudomyxoma Peritonei

Advanced Pseudomyxoma Peritonei in which the PMP has progressed to the extent where it is very difficult or even impossible to surgically remove all the tumors present or to de-bulk the tumour mass present on the peritoneum. Advanced PMP mainly encompasses more intense and serious types of tumor, (Peritoneal Mucinous Carcinomatosis or PMCA) and offers treatment and management concerns.

Free Consultation on WhatsApp

Appendix Pseudomyxoma Peritonei

Appendix Pseudomyxoma Peritonei (PMP) implies a rare syndrome whereby appendiceal mucin-secreting tumors migrate to the peritoneal space thereby forming mucinous pools. Appendix is the primary site of origin of PMP; however, the tumor may also originate in other mucin-producing structures within the abdomen.

Pseudomyxoma Peritonei Ovarian Cancer

Pseudomyxoma Peritonei (PMP) is a significantly different entity than ovarian cancer although there may be an association between the two in situations where PMP may involve ovarian metastases or may originate from primary ovarian tumors.

Why is a Pseudomyxoma Peritonei treatment needed?

Management of Pseudomyxoma Peritonei (PMP) should be promptly sought because if the disorder is left alone, it worsens and affects the patient’s quality of life. Pseudomyxoma Peritonei is not similar to a simple most accumulation of mucin; it occurs as a result of the worsening effects of mucin-producing tumor cells that invade and gradually erode organs within the abdomen. Here's why treatment is necessary:

• Prevent Abdominal Organ Dysfunction
• Alleviate Symptoms
• Stop Disease Progression
• Reduce Risk of Complications
• Prolong Survival
• Improve Quality of Life
• Prevent Fatal Outcomes

Pseudomyxoma Peritonei Symptoms

It may take several weeks to years for symptoms to manifest and are frequently ambiguous hence difficult to diagnose. Primarily symptoms appear, because of mucinous material, which forms in the peritoneal cavity and apply pressure on the organ.

Common symptoms include:

• Abdominal Pain or Discomfort
• Feeling of Fullness
• Constipation
• Diarrhea
• Bowel Obstruction
• Weight Changes
• Pelvic Discomfort or Pain
• Ovarian masses
• Fatigue
• Loss of Appetite

Risk Factors of Pseudomyxoma Peritonei Treatment

Pseudomyxoma Peritonei management, particularly Cytoreductive surgery and Hyperthermic intraperitoneal chemotherapy, is challenging and associated with dangers. These risk factors are attributed to the intrusiveness of the procedures and general condition of the patient and the severity of the disease respectively.

Below are the primary risk factors and complications associated with PMP treatment:

• Bleeding
• Infection
• Organ damage
• Bowel complications
• Damage to peritoneal tissues
• Nausea or Vomiting
• Fatigue

Causes of Pseudomyxoma Peritonei Treatment

The reasons for seeking treatment for Pseudomyxoma Peritonei (PMP) are inherent in the very character and development of this pathology. This makes it important that treatment is given to manage the main pathology and its complications.

Here’s a breakdown of the reasons (or causes) that necessitate treatment:

• Accumulation of Mucin in the Peritoneal Cavity
• Progressive Disease Nature
• Risk of Bowel Obstruction
• Abdominal Organ Dysfunction
• Prevention of Fatal Complications
• Reduction of Symptoms
• Control of Tumor Spread
• Improvement of Quality of Life
• Risk of High-Grade Disease Transformation

Free Consultation on WhatsApp

Pseudomyxoma Peritonei Diagnosis

PMP is clinically and radiologically suspected, and frequently pathologically confirmed during surgery through a histopathological examination. It is important that the disorder be diagnosed as early as possible in order that the best course of action can be taken.

• Clinical Evaluation
• Imaging Studies such as CT Scan, MRI, Ultrasound
• Laboratory Tests
• Histopathological Examination
• Diagnostic Laparoscopy
• Differential Diagnosis
• Diagnosis during Surgery

Pseudomyxoma Peritonei Surgery

Surgery is the initial line of treatment of Pseudomyxoma Peritonei (PMP) with goals of tumor resection as well as elimination of tumor cells and mucinous material from the peritoneal cavity. PMP is mainly treated surgically, the best approach to surgery being Cytoreductive Surgery (CRS) alongside Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Cytoreductive Surgery

Purpose:

• All visible tumors and mucinous deposits should be excised.
• Reduce symptoms associated with abdominal enlargement, pressure on organs or on obstructions.

Procedure:

• Invasive treatments for the specific areas of the abdomen that were seen to be affected.

May involve removal of:

• Appendix (appendectomy).
• Peritoneum (peritonectomy).
• Tumours localized in organ appendages like intestines; ovaries; uterus; spleen; or liver in case they are involved.
• Surgery aims at the least invasive approach while removing all demonstrable malignant disease at the time of surgery.

Hyperthermic Intraperitoneal Chemotherapy

Purpose:

• Infuse warm chemotherapy into the stomach cavity to eliminate any microscopically residual tumor.
• Lower the chance of the cancer coming back.

Procedure:

• Basically, after CRS, a hot chemotherapy solution is pumped through the abdominal cavity.
• An additional involved treatment, called chemotherapy, is administered for 60- 120 min at a water temperature ranging from 41-43 °C (105.8- 109.4°F).
• The heat also increases the penetration and actions of the drug against tumor cells.

Recovery

• Hospital Stay: Average of 10–14 days in total; may require time in an ICU.
• Recovery Time: Taking longer to heal can be between 3-6 months and may even more depending on the type of surgery undertaken.
• Follow-Up: Imaging and tumor marker assays every 3 months for the first year and every 6 months for the second year and then annually thereafter for evidence of disease relapse.
• Palliative care to help relieve symptoms and the general care to speed the recovery process.

Success Rate of Pseudomyxoma Peritonei Treatment

The survival rate ranges from 50–80%, depending on the factors including the grade of the disease, the extent of tumor spread, the patient’s overall health, and the type of treatment used.

Best Hospitals for Pseudomonas Peritonei

• Artemis Hospital, Gurgaon
• Medanta-The Medicity, Gurgaon
• Fortis Memorial Research Institute, Gurgaon
• Max Hospital, Saket
• BLK-Max Super Speciality Hospital, New Delhi

Best Oncologists for Pseudomonas Peritonei

• Dr. Parveen Yadav
• Dr. Ashok Kumar Vaid
• Dr. Vinod Raina
• Dr. Harit Chaturvedi
• Dr. Surender Kumar Dabas

Why Choose GetWellGo for Pseudomonas Peritonei Treatment?

Opting GetWellGo for Pseudomyxoma Peritonei (PMP) treatment has a number of benefits because this health-care center is patient-oriented and experienced in managing complicated diseases.

Here’s why it might be an excellent choice for PMP treatment:

• Expert Medical Team
• Advanced Surgical Technology
• Language Support
• Travel Assistance
• Accommodation Support
• Visa Assistance

Conclusion

Pseudomyxoma Peritonei (PMP) is a rare and tough clinical presentation wherein mucinous material gathers in the peritoneal cavity usually due to the rupture of an appendiceal or other organ keloids. However, PMP develops over time, and in its advanced stages it interferes with bowel function, organ dysfunction, and the patient’s overall quality of life.

The mainstay of treatment consists of CRS and HIPEC which offer the best opportunities for long-term survival and disease control particularly in low grade histological types. Something like early diagnosis, treatment programs and care of specialized medical teams used to operate on breast cancer patients is important when it comes to the probability of a patient’s success.

Depending on the grade and extent of the disease, the prognosis might be rather different, but the survival rate and quality of life is improved. The treatment has evolved and enhanced the prospects of patients with such condition. If adequately observed, managed, and followed up, PMP patients can have good outcomes, and they do not develop serious consequences of the disease.

FAQ

1. What are the advantages of Cytoreductive Surgery (CRS) and HIPEC?

• Complete Cytoreduction: CRS has the intent of eradicating all tumour cells visible and reduce instances of recurrent diseases, disease-free rates and survival.
• Targeted Chemotherapy: HIPEC in high concentration directly treats the peritoneal cavity and has less chemosystemic toxicity and effectively for the residual cancer.
• Improved Survival Rates: When used together, CRS and HIPEC increase patient survival more effectively than in other peritoneal malignancies, particularly in those deemed low-grade PMP.
• Symptom Relief: Reduces symptomatology like, abdominal pain, distension and bowel obstruction so enhancing the quality of life of the patient.
• Potential for Long-Term Remission: Easily cured patients and those treated early can live a normal life or even have the disease wiped out completely.

2. What is the effectiveness of PMP treatment?

• Low-Grade PMP: With regard to survival rate, the 5 years survival of the low-grade PMP ranges from 60 to 90%, whilst the 10 years survival of the same ranges between 50 to 80%.
• High-Grade PMP: The five-year survival rate of high-grade PMPs is between 30%–60%, and the ten-year survival rate of the same is 20%–40%. Still, the prognosis is worse in high-grade cases, but both CRS and HIPEC provide benefits for such patients.
• Overall Survival: The overall 5-year survival for all cases of PMP that have undergone CRS and HIPEC ranges from 50–80% depending with the disease stage and the patients’ characteristics.

3. What is the Success rate of PMP Treatment?

• Disease Grade: Low-grade PMP has a significantly higher curative rate compared with high-grade PMP because of the slower trend of disease development.
• Completeness of Cytoreduction: The degree to which the surgeon can perform an R0 resection which translated to a CC score in the study has a direct impact on survival.
• Tumor Spread: The localisation and extent of PMP within the peritoneal cavity can therefore present difficulties in achieving maximum levels of cytoreduction.
• Patient Health: Complication wise surgery and recovery aspect related to overall health, age and the presence of other medical problems.